SCHEMBL48378

SCHEMBL48378

CCOC(=O)CCN=C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.45
GAA P10253 2/20 0.44
MGAM O43451 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
ALDH1A1 P00352 6/20 0.41
TRPA1 O75762 1/20 0.41
CYP4F2 P78329 2/20 0.38
CYP4A11 Q02928 2/20 0.38
NR1I2 O75469 1/20 0.37
PGR P06401 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
PTGS2 P35354 1/20 0.37
PDE4D Q08499 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
TSHR P16473 2/20 0.36
HSD17B10 Q99714 2/20 0.36
ALOX15 P16050 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49063 0.88 CYP1A2 (0.52) CYP1A2GAAMGAMSIMGAM2
SCHEMBL11260906 0.85 CYP1A2 (0.48) CYP1A2GAAMGAMSIMGAM2
SCHEMBL11455382 0.85 CYP1A2 (0.48) CYP1A2GAAMGAMSIMGAM2
SCHEMBL1201485 0.85 CYP1A2 (0.48) CYP1A2GAAMGAMSIMGAM2
SCHEMBL575912 0.84 DGKA (0.42) ALDH1A1L3MBTL1
SCHEMBL30234219 0.82 GAA (0.36) CYP1A2GAAMGAMSIMGAM2
SCHEMBL1457047 0.82 CYP1A2 (0.44) CYP1A2GAAMGAMSIMGAM2
SCHEMBL10944383 0.82 CYP1A2 (0.44) CYP1A2GAAMGAMSIMGAM2
SCHEMBL10451052 0.81 DGKA (0.48) ALDH1A1TSHR
SCHEMBL11854167 0.81 ADRA2A (0.35) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 624 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116284102-A Preparation method of silane coupling agent and application of silane coupling agent in polylactic acid composite material 吉祥三宝高科纺织有限公司 2023-06-23 CN claimed
EP-0769955-B1 NON-ANTIGENIC AMINE DERIVED POLYMERS AND POLYMER CONJUGATES ENZON INC (US) 2004-03-10 EP claimed
US-5730990-A Non-antigenic amine derived polymers and polymer conjugates ENZON, INC. (US) 1998-03-24 US claimed
EP-0769955-A4 NON-ANTIGENIC AMINE DERIVED POLYMERS AND POLYMER CONJUGATES ENZON INC (US) 1997-11-05 EP claimed
EP-0769955-A1 NON-ANTIGENIC AMINE DERIVED POLYMERS AND POLYMER CONJUGATES ENZON, INC. (US) 1997-05-02 EP claimed
WO-1996000080-A1 NON-ANTIGENIC AMINE DERIVED POLYMERS AND POLYMER CONJUGATES ENZON, INC. (US) 1996-01-04 WO claimed
EP-4678234-A1 ANTAGONIST HETEROCYCLIC COMPOUNDS INVOLVED IN THE CGAS-STING ROUTE Centre National de la Recherche Scientifique (FR) 2026-01-14 EP disclosed
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 ZHOU YUHANG (US) 2025-09-11 US disclosed
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-06-26 US disclosed
EP-4499628-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-02-05 EP disclosed
US-20240297344-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-05 US disclosed
EP-4380990-A1 DUAL-CURE RESIN COMPOSITION COMPRISING URETDIONE-CONTAINING COMPOUND AND ITS USE IN 3D PRINTING BASF SE (DE) 2024-06-12 EP disclosed
CN-117836344-A Dual cure resin composition comprising uretdione containing compounds and use thereof in 3D printing 巴斯夫欧洲公司 2024-04-05 CN disclosed
US-4171438-A 0-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents BRISTOL-MYERS COMPANY (US) 1979-10-16 US disclosed
US-4118566-A Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents BRISTOL-MYERS COMPANY (US) 1978-10-03 US disclosed
US-4100346-A Certain 7(o-amino-methyl- or methylaminomethylphenyl- or cyclohexadienyl- or thienylacetamide)-3[1-carboxymethyl-(or ethyl- or propyl-)-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids BRISTOL-MYERS COMPANY (US) 1978-07-11 US disclosed
US-4068066-A ANTIBIOTICS BRISTOL-MYERS COMPANY (US) 1978-01-10 US disclosed
US-4065622-A O-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents BRISTOL-MYERS COMPANY (US) 1977-12-27 US disclosed
US-4029772-A FOR TREATMENT OF PANCREATITIS MERCK & CO., INC. (US) 1977-06-14 US disclosed
US-4013648-A BETA-LACTAM ANTIBIOTICS BRISTOL-MYERS COMPANY (US) 1977-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281424-A1 SMALL MOLECULE ANTAGONISTS OF PF4 PF4, F12, F2 CYP1A2 3800/4885GAA 4440/4885MGAM 4712/4885
US-20250205344-A1 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS CRBN, AR, GNRHR CYP1A2 1201/4885GAA 3074/4885MGAM 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.